EN DE
Watch Bioqual Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bioqual Inc (BIOQ) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Bioqual Inc stock $23.51, price $31.00, that is 24.2% below the price, quality 41 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BI Bioqual Inc logo Thin data Nov 3, 2026

Bioqual Inc

BIOQ · US
Expensive, weak quality

Our calculation puts a fair price 24% below what the stock costs today.

Low debt
Quality 41/100
Fair value $23.51 · Overvalued
Weak Growth (revenue 5y −7.1 %/yr in USD)
Loss-making · -11.0% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 10/100 · thin data
Thin data
⚠ Thinly traded
Watch Bioqual Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$105.34 $12.06 Fair Value $23.51 Jun 2015 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range $12.06 – $105.34 · fair‑value band $17.54 – $35.08 · the $31.00 price screens above the $23.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Bioqual in your weekly email

Every Wednesday you see whether Bioqual is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

Show moreShow less

The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models.

In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services.

Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.

Stock analysis

Bioqual Inc (BIOQ) currently trades at $31.00, while our model-based Fair Value estimate is $23.51, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $17.54 (bear) to $35.08 (bull), the price of $31.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Bioqual Inc reported revenue of $39.9M in FY2026 versus $66.2M in FY2022, a compound −11.8%/yr. Reported net income was −$4.2M in FY2026.

Key figures

Market cap $27.7M Micro · P/S ratio 0.69 · EPS (TTM) $2.59 · Dividend yield 1.6% · Net margin −10.4% · Return on equity −13.0% · Return on assets (EBIT) 0.4% (5-year average) · Operating margin −7.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −24%, BIOQ screens richer than that median.

Fair Value models

Bear $17.54 Fair Value $23.51 Bull $35.08
Price $31.00 · Downside -24.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then ($1.15 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $17.54 $23.51 $35.08 54
All 1 models by family
Asset-Based
NCAV (Graham) $17.54 $23.51 $35.08 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 100
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−18.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Start year 2021 (pandemic). Over 10 years: +1.9% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.8% (2021) → −11.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

BIOQ screens overvalued: fair value 24% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Bioqual Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −24.2% · Above median
Profitability
Return on assets −6.1% · Below median
Net margin (12 months) −11.0% · Bottom 25%
Operating margin (12 months) −7.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.0% · Below median
Dividend yield (12 months) 1.6% · Below median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.86× · Cheapest 25%
P/S (12 months) 0.69× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)15 · sector 39
PAST (return on equity)0 · sector 15
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)32 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs BIOQ
IQVIA Holdings IQV $271.83 $299.01 +10% vs BIOQ
Illumina, Inc ILMN $213.13 $234.44 +10% vs BIOQ
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs BIOQ
Danaher Corporation DHR $230.25 $209.18 −9% vs BIOQ
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs BIOQ
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs BIOQ
Agilent Technologies, Inc A $174.76 $64.53 −63% vs BIOQ
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs BIOQ
Waters Corporation WAT $457.60 $91.26 −80% vs BIOQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioqual Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bioqual Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIOQ

Frequently asked questions

Is Bioqual Inc (BIOQ) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $23.51 versus the last price from Oct 28, 2026 of $31.00, about 24% lower (overvalued).
What is the fair value of BIOQ?
Our model-based fair value for Bioqual Inc is $23.51 (as of Nov 3, 2026), built from audited fundamentals. Last price (from Oct 28, 2026): $31.00.
What is the quality score of BIOQ?
Bioqual Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioqual Inc (BIOQ)?
Our model-based price target is the fair value of $23.51 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario $17.54, optimistic scenario $35.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioqual Inc stock forecast for 2026?
Our models put fair value at $23.51, about 24% lower versus the last price from Oct 28, 2026 of $31.00 (overvalued). Cautious scenario $17.54, optimistic scenario $35.08. The calculation is refreshed regularly with new filings.
What is the revenue of Bioqual Inc (BIOQ)?
Bioqual Inc reported trailing-twelve-month revenue of about $40.2M (latest available figure, as of Nov 3, 2026).
Does Bioqual Inc pay a dividend?
Bioqual Inc currently shows a dividend yield of 1.61% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Bioqual Inc (BIOQ)?
Bioqual Inc has a dividend yield of 1.6%.
What is the intrinsic value of Bioqual Inc (BIOQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioqual Inc it is $23.51 per share (as of Nov 3, 2026), against a price of $31.00. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Bioqual Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, BIOQ trades above its calculated fair value: price $31.00, fair value $23.51, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOQ?
No. The price is what the market pays today ($31.00); the fair value is what the company's own numbers justify ($23.51). For Bioqual Inc the two are $7.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioqual Inc worth?
The market values Bioqual Inc at about $27.7M (market capitalisation, as of Nov 3, 2026). Per share that is $31.00; our models calculate a fair value of $23.51 per share.
What do the bullish and bearish scenarios say about BIOQ?
Our models span a range for Bioqual Inc: cautious scenario $17.54, base $23.51, optimistic $35.08 per share (as of Nov 3, 2026, price $31.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioqual Inc (BIOQ)?
Balance-sheet figures for Bioqual Inc (as of Nov 3, 2026): return on equity −13.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is BIOQ from its 52-week high?
Bioqual Inc trades at $31.00, about 23% below its 52-week high of $40.00 and 1% above the low of $30.64 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $23.51 is for.
Which stocks are comparable to Bioqual Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioqual Inc stock attractive at the current price?
The data as of Nov 3, 2026: price $31.00, calculated fair value $23.51 (−24%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOQ calculated?
We run Bioqual Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $23.51 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bioqual Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioqual Inc (BIOQ)?
The latest price we hold is from Oct 28, 2026 and stands at $31.00. Our model-based fair value is $23.51, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioqual Inc right now?
Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($17.54 to $35.08) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Bioqual Inc

How large is the market capitalisation of Bioqual Inc (BIOQ)?
The market capitalisation of Bioqual Inc is $27.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bioqual Inc (BIOQ)?
The price-to-sales ratio of Bioqual Inc is 0.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bioqual Inc (BIOQ)?
Earnings per share at Bioqual Inc are $2.59. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bioqual Inc (BIOQ)?
The dividend yield of Bioqual Inc is 1.6% (payout 19.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bioqual Inc (BIOQ)?
The net margin of Bioqual Inc is −10.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bioqual Inc (BIOQ)?
The return on equity (ROE) of Bioqual Inc is −13.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioqual Inc (BIOQ)?
On an EBIT basis the return on assets of Bioqual Inc is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioqual Inc (BIOQ)?
The operating margin of Bioqual Inc is −7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioqual Inc (BIOQ)?
Revenue at Bioqual Inc is growing +3.0% versus a year earlier (3y avg −13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bioqual Inc (BIOQ)?
Earnings per share at Bioqual Inc are growing +240% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bioqual Inc (BIOQ) generate?
The free cash flow of Bioqual Inc is −$66.8K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bioqual Inc (BIOQ) carry?
The net debt of Bioqual Inc is $21.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bioqual Inc in the live analysis

One click puts Bioqual Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.